SCHEMBL1103400

SCHEMBL1103400

Cc1cc(C)cc(-c2c3ccccc3c(-c3ccccc3)c3c2cnc2ccccc23)c1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.47
MAPT P10636 4/20 0.47
HTT P42858 3/20 0.47
NPSR1 Q6W5P4 2/20 0.47
SMN1; SMN2 Q16637 2/20 0.47
HPGD P15428 2/20 0.44
PSMB5 P28074 1/20 0.42
SSTR2 P30874 1/20 0.40
ABCG2 Q9UNQ0 2/20 0.39
LMNA P02545 1/20 0.39
TP53 P04637 1/20 0.39
TLR7 Q9NYK1 1/20 0.39
ESR1 P03372 2/20 0.39
ESR2 Q92731 2/20 0.39
GRM5 P41594 1/20 0.38
TOP2A P11388 1/20 0.38
PDPK1 O15530 1/20 0.37
ABCB1 P08183 1/20 0.36
CYP3A4 P08684 2/20 0.36
CYP2C9 P11712 2/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1103262 0.96 SSTR2 (0.42) ALDH1A1MAPTHTTNPSR1SMN1; SMN2
SCHEMBL1103411 0.91 ALDH1A1 (0.52) ALDH1A1MAPTHTTNPSR1SMN1; SMN2
SCHEMBL1103402 0.90 ALDH1A1 (0.52) ALDH1A1MAPTHTTNPSR1SMN1; SMN2
SCHEMBL1103260 0.88 HTT (0.48) ALDH1A1MAPTHTTNPSR1SMN1; SMN2
SCHEMBL1105452 0.88 ESR1 (0.43) ALDH1A1MAPTHTTNPSR1SMN1; SMN2
SCHEMBL1103407 0.87 ALDH1A1 (0.43) ALDH1A1MAPTHTTNPSR1SMN1; SMN2
SCHEMBL1103261 0.87 ALDH1A1 (0.48) ALDH1A1MAPTHTTNPSR1SMN1; SMN2
SCHEMBL1103377 0.87 ESR1 (0.41) ALDH1A1MAPTHTTNPSR1SMN1; SMN2
SCHEMBL1103486 0.86 ESR1 (0.42) ALDH1A1MAPTHTTNPSR1SMN1; SMN2
SCHEMBL1103449 0.86 ESR1 (0.42) ALDH1A1MAPTHTTNPSR1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8153279-B2 Organic electroluminescent compounds and organic electroluminescent device using the same GRACEL DISPLAY INC. (KR) 2012-04-10 US disclosed
US-8153279-B2 Organic electroluminescent compounds and organic electroluminescent device using the same GRACEL DISPLAY INC. (KR) 2012-04-10 US disclosed
US-20100033083-A1 Novel organic electroluminescent compounds and organic electroluminescent device using the same GRACEL DISPLAY INC. (KR) 2010-02-11 US disclosed
US-20100033083-A1 Novel organic electroluminescent compounds and organic electroluminescent device using the same GRACEL DISPLAY INC. (KR) 2010-02-11 US disclosed
EP-2147962-A1 Azaanthracene-derivatives and organic electroluminescent device using the same Gracel Display Inc. (KR) 2010-01-27 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100033083-A1 Novel organic electroluminescent compounds and organic electroluminescent device using the same ORMDL3, OCIAD2, OCIAD1 ALDH1A1 1015/4885MAPT 3162/4885HTT 4390/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.